|
|
 |
|
Viewing report
|
|
|
|
World Market for Addiction Disorders, 2009–2016, The Future Therapies for Substance Dependence and Impulse Control
Spectra Intelligence , Oct 2009, Pages: 81
The report estimates that the current market for addiction disorders is valued at US$3.2 billion and this is forecast to increase 19% to US$3.8 billion by 2016.
A comprehensive update of the 2005 edition
Examines the market for addiction pharmacotherapies currently estimated at US$2 billion
The substance dependence field is transforming into a high-growth market opportunity. Supported by the success of Pfizer's recently launched Chantix/Champix, which is on track for blockbuster status in the smoking cessation sector, pharmacotherapies in development for alcohol, narcotic, and nicotine dependencies are poised to radically change the addiction treatment landscape in this difficult-to-treat patient population.
The report estimates that the current market for addiction disorders is valued at US$3.2 billion and this is forecast to increase 19% to US$3.8 billion by 2016.
The World Market for Addiction Disorders, 2009 2016: Future Therapies for Substance Dependence and Impulse Control, will introduce the reader a specialty pharmaceutical market which is positioned for high-growth based on analysis of marketed and pipeline drugs, company activities, and addiction disorder demographics.
Therapy area forecasting and illustrative comparative sales data is presented to gain insight into leading products with sales estimates to 2016.
Objectives of Report
The objectives of this 80 page report are to provide an in-depth analysis of the global addiction pharmacotherapeutic market. Included in this study are analyses of key therapy areas, R&D programs, and innovating companies and products. The reader will benefit from market forecasts, pooled knowledge of recent industrial activities and events, and from analytical discourse, which is intended to stimulate growth and create new market opportunities.
Report Highlights Include:
- The current market for addiction disorders is valued at US$3.2 billion, up from US$2 billion in 2005
- Critical analysis of alcohol, cocaine, opiate, and nicotine addictions
- Review of epidemiological, aetiological, and demographic data for addiction disorders
- Analysis of over 10 key marketed products and inclusion of 34 R&D candidates identified in preclinical to clinical stages of development for addiction disorders
- Sales estimates (US$) to 2012 for major therapy areas
- Strategic insights for life-cycle optimization and product development
- Critical evaluation of leading addiction pharmacotherapies
- Emerging markets identified and sector analysis
- Trend analysis of industry events and activities over past 2 years
- Detailed R&D themes and clusters by addiction area
- Data generation on sector and market values between 2004 and 2012 and therapy forecasts by 2020 (US$)
- High revenue-yielding prospects identified with projected sales estimations
- R&D pipeline positioning for novel candidates
- Market insights for product development and drug promotion
What you can learn from this report:
- Which addiction therapies are the current and potential future market leaders
- How companies are reformulating products for addiction indications
- Which premarket addiction pharmacotherapies are identified as high-value products
- Which companies are developing drugs for addiction disorders
- Sales predictions to 2016 for addiction pharmacotherapies
- What the likely impact of pipeline products will be on value growth of the addiction market over the 10 years
- Which addiction subsectors could be niche market opportunities
- What the future outlook holds for addiction pharmacotherapies
- Insight into R&D trends for alcohol, cocaine, opiate, and nicotine addictions
- Which molecules and compounds are main R&D clusters for dependency disorders
- Which of the pipeline candidates are top prospects in the addiction market over the next decade and to 2025
Report Contains:
- Detailed survey and analysis of the current and future global addiction disorder market
- Comprehensive update on key marketed products indicated for alcohol, narcotic, and nicotine dependency disorders
- Review of epidemiological, demographic, aetiological, and therapeutic data associated with addiction disorders
- Market analysis and insight of key addiction pharmacotherapies and pipelines
- Market value predictions of individual marketed products to 2016
- Insight and trend analysis of pipeline products for addiction disorders
- Review of promising pipeline products and potential market opportunities
- Extensive coverage of the R&D pipeline for addiction disorders
- Guide to leads for potential licensing opportunities
About the Author
Tim Atkinson has authored over 30 pharmaceutical market research reports and has expertise in drug discovery, drug development and drug delivery in addition to generics, parallel trade, and numerous therapeutic areas such as hormonal and metabolic disorders, oncology, and infection.
He has undertaken assignments for leading pharmaceutical companies such as Pfizer and GlaxoSmithKline, as well as for healthcare agencies and publishers such as Global Business Insights, IMS Health, and Informa Healthcare.
He worked previously as a Biomedical Scientist within the UK NHS and is a trained Medical Writer/Editor and has worked for publishers such as Thomson Science, Mosby, Churchill Livingstone and Current Science Group.
He holds an MSc in Health and Disease from Birkbeck College, London and he is a member of the Royal Society of Chemistry, Institute of Biology, and British Society for Immunology.
Customers who bought this item also bought
Substance Abuse Disorders: A focus on the smoking cessation and alcohol addiction markets
Opportunities in the Pharmacotherapy of Addiction
Understanding Nicotine and Tobacco Addiction
Healing Addiction: An Integrated Pharmacopsychosocial Approach to Treatment
Pipeline Insight: Substance Dependence - Part II: Alcohol
Addiction at Work
Addiction Treatment Homework Planner, 4th Edition
Food Cravings and Addiction Update
Pipeline Insight: Substance Dependence - Part I: Nicotine
The Addiction Progress Notes Planner, 3rd Edition
Pipeline and Commercial Insight: Nicotine Dependence - Chantix issues overshadow vaccine potential
Nicotine Dependence Market Forecast
|
|
|
|
